- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04958434
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study has 2 parts. Part A is a dose escalation portion where the patients will be doses every three weeks following an accelerated 3+3 design. This portion will enroll approximately 25 patients with locally advanced or metastatic cancers.
Part B is an expansion portion where approximately 30 additional patients will be dosed at the recommended dose level every 3 weeks. This part will include patients with locally advanced or metastatic HPV related malignancies.
The trial will last approximately 2 years, with assessments including safety labs, ECGs, PKs and PDs and CT/MRI tumor assessments, based on the Q3W dosing schedule.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Tina Rahbarnia
- Phone Number: 949 233 2209
- Email: Tina.Rahbarnia@ppd.com
Study Contact Backup
- Name: Meriam Djemai Zoghlache
- Phone Number: +33 761 539 165
- Email: Meriam.DjemaiZoghlache@ppd.com
Study Locations
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research
-
San Antonio, Texas, United States, 78229
- Next Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to provide signed and dated informed consent
- Patients with histologically or cytologically confirmed, locally advanced or metastatic solid tumors, evaluable by RECIST v1.1. (Part B includes metastatic HPV+ malignancies)
- Subject who has tumor progression during or after prior therapy and for whom no standard therapy exists that would confer clinical benefit.
- At least one measurable lesion per RECIST 1.1 (Part B only).
- Eastern Cooperative Oncology Group Performance Status (ECOG PS)0~1.
- Provide archived tumor tissue samples
- Adequate organ function
Exclusion Criteria:
- Concurrent malignancy within 3 years prior to entry other than adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma, prostate cancer not requiring treatment (with or without resection), ductal carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma.
- Untreated or symptomatic central nervous system (CNS) metastases.
- Any unresolved Grade 2 or greater toxicity from previous anticancer therapy except alopecia.
- Active leptomeningeal disease.
Active autoimmune diseases or history of autoimmune diseases that may relapse, with the following exceptions:
- Controlled type 1 diabetes
- Hypothyroidism (provided it is managed with hormone-replacement therapy only)
- Controlled celiac disease
- Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or alopecia)
- Any other disease that is not expected to recur in the absence of external triggering factors
Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of investigational product, with the following exceptions:
- Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)
- Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption
- Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)
- History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases, including but not limited to pulmonary fibrosis, active pneumonitis.
- Severe cardiovascular disease, including cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina, New York Heart Association class III or IV heart failure or uncontrolled arrhythmia within 6 months of first dose.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 2 weeks of screening.
- Clinically significant bleeding within three months of the first dose.
- Uncontrolled hypertension, defined as systolic ≥150 mm Hg or diastolic ≥90 mm Hg maintained over time and despite antihypertensive treatment.
- Patients with QTcF > 480 ms on screening ECG or with a history of additional risk factors for TdP (e.g., heart failure, hypokalemia,family history of Long QT Syndrome)
- Pregnant or nursing.
- Known human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
- A serious nonmalignant disease (e.g., psychiatric, substance abuse, uncontrolled intercurrent illness, etc.) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study.
Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose (i.e., with use of disease modifying agents, systemic corticosteroids or immunosuppressive drug).
• Subjects with Type 1 diabetes mellitus (TD1M), hypothyroidism requiring only hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll.
- A history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- < 4 weeks after any major procedures/surgery; clinically significant unhealed wound; any unhealed ulceration in GI prior to first dose of TST005.
- History of severe immune-related adverse effects from checkpoint inhibitor (CPI) therapy (NCI CTCAE Grade 3 or 4) with the exception of endocrinopathy managed with replacement therapy or subjects who discontinued CPI therapy for CPI-associated toxicity or intolerability.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A - Dose Escalation
Dosed every 3 weeks IV with TST005, starting dose is 1 mg/kg, and 5 dose levels will be tested.
|
TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
|
Experimental: Part B - Dose Expansion
Participants with any kind of advanced or HPV metastatic solid tumors dosed Q3W with the Part A Q3W recommended dose of TST005
|
TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A - Determine the maximum tolerated dose (MTD) or recommended Phase 2 dose(s) (RP2D)
Time Frame: Up to 90 days following last dose
|
As measured by the number of participants experiencing a dose limiting toxicity (DLT) in each dosing cohort
|
Up to 90 days following last dose
|
Part B - Patient safety as characterized by frequency and severity of adverse events
Time Frame: Up to 90 days following last dose
|
Characterize the safety profile of TST005 including the frequency and severity of treatment-emergent adverse events.
|
Up to 90 days following last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A - Area under Plasma concentration vs. time curve (AUC) for TST005
Time Frame: Up to 90 days following last dose
|
Observe changes in AUC over time
|
Up to 90 days following last dose
|
Part A - Peak Plasma concentration (Cmax) for TST005
Time Frame: Up to 90 days following last dose
|
Observe the maximum serum concentration
|
Up to 90 days following last dose
|
Part A - Time to maximum observed serum (Tmax) for TST005
Time Frame: Up to 90 days following last dose
|
Tmax is the time in hours / days for TST005 to reach the maximum concentration after administration
|
Up to 90 days following last dose
|
Part A - Terminal half-life of TST005
Time Frame: Up to 90 days following last dose
|
Time for serum level to decrease by 1/2 during the terminal elimination phase
|
Up to 90 days following last dose
|
Immunogenicity of TST005
Time Frame: Up to 90 days following last dose
|
To determine if the formation of Anti-drug antibodies (ADA) or neutralizing antibodies (NAb) against TST005 are observed
|
Up to 90 days following last dose
|
Part B - Assess the Objective response rate (ORR) of TST005
Time Frame: Up to 90 days following last dose
|
as measured by RECIST v 1.1 and iRECIST
|
Up to 90 days following last dose
|
Part B - Assess the Disease Control rate (DCR) of TST005
Time Frame: Up to 90 days following last dose
|
Percentage of patients that exhibit stable disease (SD), + partial response (PR), + complete response (CR)
|
Up to 90 days following last dose
|
Part B - Assess the Duration of Response of TST005
Time Frame: Up to 90 days following last dose
|
Measured by the time a patient shows response
|
Up to 90 days following last dose
|
Part B - Assess the Time to Response (TTR) of TST005
Time Frame: Up to 90 days following last dose
|
Measured by the average time patients show a response to TST005
|
Up to 90 days following last dose
|
Part B - Assess the Progression -free Survival (PFS) of TST005
Time Frame: Up to 90 days following last dose
|
Measured by the average time before patients show signs of disease progression after receiving TST005
|
Up to 90 days following last dose
|
Part B - Assess the Overall Survival (OS) of TST005
Time Frame: Up to 90 days following last dose
|
Time between treatment of TST005 and death for any reason
|
Up to 90 days following last dose
|
Collaborators and Investigators
Investigators
- Study Director: Charlie Qi, MD, Suzhou Transcenta Therapeutics Co., Ltd.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic Cancers
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingMetastatic Solid Tumor Cancers | Locally Advanced Solid Tumor CancersUnited States
-
Deciphera Pharmaceuticals LLCTerminatedMetastatic Solid Tumors | Locally Advanced Tumors | Cancers With MET Genomic Alterations | Cancers With TRK Genomic AlterationsUnited States
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Hospices Civils de LyonUnknownMetastatic or Locally Advanced Solid TumorsFrance
-
Merck Sharp & Dohme LLCCompletedMetastatic or Locally Advanced Cancer
-
German Cancer Research CenterRecruiting
-
University Medical Center GroningenActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyCompletedLocally Advanced or Metastatic Solid TumorsHungary